Big Data—a new player in the Healthcare Industry
April 2, 2015 |
Big Data is an exciting by-product of the information technology revolution and offers new ways of understanding customers.
Our previous blog explored the rise of Big Data and its importance to the market research industry. In this blog we investigate some of the ways in which big pharma have used big data and consider the specific implications for us, the healthcare market research industry.
Big data is exciting to healthcare because the integration of data sources, combined with the tremendous volume of data now available, affords pharma the chance to gain fresh insights into patient behavior and HCP decision-making, as well as make improvements to overall health system planning. Major pharma companies, such as Astra Zeneca and GSK, have been quick to embrace Big Data to gain additional market understanding. For example, Astra Zeneca recently partnered with a data analytics company, Healthcore, which analyses insurance claims. By combining large amounts of medical records with insurance claim data, AZ was able to establish the relationship between treatment effectiveness and cost of care. This helps the company to identify more effective and affordable treatment for patients. This level of analytics, which gives pharmaceutical companies a means of developing more effective pricing strategies, is one that traditional market research agencies are unlikely to be equipped to offer.
GSK applied Big Data analysis in order to identify target customers. By working with data analytics company Occam, GSK aimed to “identify people who are mentioning a particular brand of ours but also track everything else they are talking about in the public domain to build a customer profile”, said James Parker, GSK’s CRM consultant. In this example, Big Data could realise real-time monitoring and reporting, in a way which traditional market research agencies cannot.
Consequently, we as market researchers must face the question: With Big Data analytics on the increase, will primary market research become redundant?
We would like to think not. There are two skills required by both researchers conducting traditional primary market research and Big Data research. The first is an in-depth knowledge of the industry. This arms researchers with the ability to design the best solution to answer the business question. Secondly, researchers require the ability to analyze the findings and provide actionable recommendations which help companies increase their profitability and sustainability.
However, there are distinct differences between the two types of research in terms of approach and analysis. One characteristic of current Big Data research is that it is largely retrospective and mainly uses existing data. Sometimes the volume of data means that it can be used as a predictor of future behaviour, but this is open to misinterpretation. Big Data analysis sometimes gives ambiguous findings because of the limited context around the business question being addressed. Overall, Big Data is useful for making sense of the big picture and identifying overall trends and patterns but sometimes it can’t be relied upon to answer business questions at a more granular level.
Primary market research takes a more structured approach. Data collection and analysis are controlled, meaning the findings should directly answer the research objective and address the business question. It is very valuable when you want to gather in-depth insights from specific types of audiences.
So what does the future hold for the healthcare market research industry? Well we think ideally we should be working in partnership to deliver an integrated solution. Primary market research will still be required to fill the gaps in understanding which Big Data is unable to provide. And primary market research agencies, should explore the possibility of partnering with Big Data analytics agencies, or even developing in-house analytics team, in order to provide a one-stop market research service for clients.
Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges. Find out more here: http://bit.ly/1F7rEiF
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Blog: The Cost of Counterfeits
The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.
Video: Self-pay and Emerging Markets
A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...
News: Therapy Watch HCV expands into 4 additional EU markets
The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...
News: Research Partnership launches new patient report – Living with Ulcerative Colitis
Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...
Summer Intern experience at Research Partnership
We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research
Beyond Andrology: Trends in Men’s Health in Emerging Markets
Published in eyeforpharma July 2016 by Rachel Howard
Infographic: HIV Market Snapshot
Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...
Infographic: The vaccine opportunity in Asia
As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...
Webinar: What next for biosimilars?
Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST
Understanding the Patient Journey
The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme. Technology...